A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super responders’ to Merck & Co’s Keytruda (pembrolizumab) immunotherapy i
Switzerland’s Ferring Pharmaceuticals has joined with US investor Blackstone Life Sciences to pump $570 million into a bladder cancer gene therapy project.
